185,619 Shares in Establishment Labs Holdings Inc. $ESTA Bought by ADAR1 Capital Management LLC

Key Points

• ADAR1 Capital Management acquired 185,619 Establishment Labs shares worth approximately $15.9 million, representing about 0.62% of the company. Institutional investors collectively own 72.91% of ESTA.
• Analyst sentiment is broadly positive: eight analysts rate the stock a Buy and one rates it a Sell, producing a “Moderate Buy” consensus and an average price target of $100.25.
• Establishment Labs reported quarterly revenue of $67.54 million, up 31.7% year over year and above estimates, but its adjusted loss of $0.39 per share missed expectations. Shares opened at $72.15, below the company’s $85.74 50-day moving average.

ADAR1 Capital Management LLC acquired a new stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 185,619 shares of the company's stock, valued at approximately $15,928,000. ADAR1 Capital Management LLC owned approximately 0.62% of Establishment Labs as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ESTA. KBC Group NV bought a new stake in shares of Establishment Labs during the 1st quarter valued at approximately $28,000. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Establishment Labs during the second quarter worth $43,000. Kestra Advisory Services LLC bought a new stake in shares of Establishment Labs during the fourth quarter worth $47,000. Quarry LP acquired a new position in shares of Establishment Labs during the third quarter worth $34,000. Finally, State of Wyoming acquired a new position in shares of Establishment Labs during the second quarter worth $87,000. Institutional investors own 72.91% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ESTA. Weiss Ratings reissued a "sell (e+)" rating on shares of Establishment Labs in a report on Wednesday, June 24th. Needham & Company LLC upped their target price on Establishment Labs from $86.00 to $95.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. Canaccord Genuity Group set a $105.00 target price on Establishment Labs in a research report on Thursday, August 6th. TD Cowen lifted their price target on Establishment Labs from $95.00 to $117.00 and gave the company a "buy" rating in a research note on Monday, August 3rd. Finally, BTIG Research lifted their price target on Establishment Labs from $96.00 to $103.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Eight analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $100.25.

Establishment Labs Price Performance

Shares of ESTA opened at $72.15 on Wednesday. Establishment Labs Holdings Inc. has a 1 year low of $36.53 and a 1 year high of $97.59. The company has a debt-to-equity ratio of 12.11, a current ratio of 3.84 and a quick ratio of 2.52. The company has a market capitalization of $2.15 billion, a price-to-earnings ratio of -55.08 and a beta of 1.07. The business has a 50-day moving average of $85.74 and a 200-day moving average of $74.87.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.05). Establishment Labs had a negative net margin of 15.82% and a negative return on equity of 196.69%. The firm had revenue of $67.54 million for the quarter, compared to analyst estimates of $65.79 million. During the same period in the prior year, the company posted ($0.57) EPS. The business's revenue for the quarter was up 31.7% compared to the same quarter last year. As a group, equities research analysts anticipate that Establishment Labs Holdings Inc. will post -1.15 earnings per share for the current year.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company's proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company's flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source